Home > Publications database > Revisiting the growth modulon of Corynebacterium glutamicum under glucose limited chemostat conditions > print

001     885729
005     20210130010506.0
024 7 _ |a 10.3389/fbioe.2020.584614
|2 doi
024 7 _ |a 2128/25904
|2 Handle
024 7 _ |a pmid:33178676
|2 pmid
024 7 _ |a WOS:000584724900001
|2 WOS
037 _ _ |a FZJ-2020-04041
082 _ _ |a 570
100 1 _ |a Graf, Michaela
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Revisiting the growth modulon of Corynebacterium glutamicum under glucose limited chemostat conditions
260 _ _ |a Lausanne
|c 2020
|b Frontiers Media
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1602846662_16749
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Increasing the growth rate of the industrial host Corynebacterium glutamicum is a promising target to rise productivities of growth coupled product formation. As a prerequisite, detailed knowledge about the tight regulation network is necessary for identifying promising metabolic engineering goals. Here, we present comprehensive metabolic and transcriptional analysis of C. glutamicum ATCC 13032 growing under glucose limited chemostat conditions with μ = 0.2, 0.3, and 0.4 h–1. Intermediates of central metabolism mostly showed rising pool sizes with increasing growth. 13C-metabolic flux analysis (13C-MFA) underlined the fundamental role of central metabolism for the supply of precursors, redox, and energy equivalents. Global, growth-associated, concerted transcriptional patterns were not detected giving rise to the conclusion that glycolysis, pentose-phosphate pathway, and citric acid cycle are predominately metabolically controlled under glucose-limiting chemostat conditions. However, evidence is found that transcriptional regulation takes control over glycolysis once glucose-rich growth conditions are installed.
536 _ _ |a 581 - Biotechnology (POF3-581)
|0 G:(DE-HGF)POF3-581
|c POF3-581
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Haas, Thorsten
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Teleki, Attila
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Feith, André
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Cerff, Martin
|0 P:(DE-Juel1)167260
|b 4
700 1 _ |a Wiechert, Wolfgang
|0 P:(DE-Juel1)129076
|b 5
|u fzj
700 1 _ |a Nöh, Katharina
|0 P:(DE-Juel1)129051
|b 6
|u fzj
700 1 _ |a Busche, Tobias
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Kalinowski, Jörn
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Takors, Ralf
|0 P:(DE-HGF)0
|b 9
|e Corresponding author
773 _ _ |a 10.3389/fbioe.2020.584614
|g Vol. 8, p. 584614
|0 PERI:(DE-600)2719493-0
|p 584614
|t Frontiers in Bioengineering and Biotechnology
|v 8
|y 2020
|x 2296-4185
856 4 _ |y OpenAccess
|u https://juser.fz-juelich.de/record/885729/files/fbioe-08-584614.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://juser.fz-juelich.de/record/885729/files/fbioe-08-584614.pdf?subformat=pdfa
909 C O |o oai:juser.fz-juelich.de:885729
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 5
|6 P:(DE-Juel1)129076
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 6
|6 P:(DE-Juel1)129051
913 1 _ |a DE-HGF
|b Key Technologies
|l Key Technologies for the Bioeconomy
|1 G:(DE-HGF)POF3-580
|0 G:(DE-HGF)POF3-581
|2 G:(DE-HGF)POF3-500
|v Biotechnology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-01-14
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-01-14
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2020-01-14
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-01-14
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT BIOENG BIOTECH : 2018
|d 2020-01-14
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2020-01-14
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2020-01-14
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
|d 2020-01-14
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2020-01-14
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-01-14
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2020-01-14
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|f 2020-01-14
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b FRONT BIOENG BIOTECH : 2018
|d 2020-01-14
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
|d 2020-01-14
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2020-01-14
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-01-14
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2020-01-14
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-01-14
920 1 _ |0 I:(DE-Juel1)IBG-1-20101118
|k IBG-1
|l Biotechnologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)IBG-1-20101118
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21